跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT02231177
NCT02231177已完成1 期

A Randomised, Double-blind, 3-way Crossover Study to Compare Pharmacokinetics and Safety of 10 μg BI 1744 CL Plus 5 μg Tiotropium Bromide Given as Fixed Dose Combination Via the Respimat® Inhaler With the Pharmacokinetics and the Safety of the Single Agents, i.e. 10 μg BI 1744 CL and 5 μg Tiotropium Bromide, Delivered Via the Respimat® Inhaler Following 21 Day-treatment Periods in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Boehringer Ingelheim0 个研究点目标入组 47 人开始时间: 2008年6月最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
47
主要终点
AUC(0-1h,ss) of Olodaterol
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to compare the systemic exposure to BI 1744 BS and tiotropium at steady state following inhalation of the fixed dose combination (FDC) of 10 μg BI 1744 CL plus 5 μg tiotropium bromide with the systemic exposure to BI 1744 BS and tiotropium at steady state following inhalation of the single agents, i.e., 10 μg BI 1744 CL and 5 μg tiotropium bromide, when administered once-daily via the Respimat® Inhaler for 21 days.

The secondary objectives were to compare the safety and tolerability (adverse events, 12-lead electrocardiogram recordings, pulmonary function testing) of BI 1744 CL and tiotropium bromide when administered as fixed dose combination or as single-agent therapy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double

入排标准

年龄范围
40 Years 至 —（Adult, Older Adult）
性别
All
接受健康志愿者
否

入选标准

  • •All patients must sign an informed consent consistent with International Conference on Harmonisation (ICH) - Good Clinical Practice (GCP) guidelines and local legislations prior to any study-related procedures, which includes medication washout and restrictions
  • •All patients must have a diagnosis of COPD and must meet the following spirometric criteria: Patients must have relatively stable airway obstruction with a post-bronchodilator forced expiratory volume in one second (FEV1) ≥ 30 % of predicted normal and < 80% of predicted normal and a post-bronchodilator FEV1 / forced vital capacity (FVC) < 70% at Visit 1
  • •Male or female patients, 40 years of age or older
  • •Patients must be current or ex-smokers with a smoking history of more than 10 pack years
  • •Patients must be able to perform technically acceptable pulmonary function tests during the study period as required in the protocol
  • •Patients must be able to inhale medication in a competent manner from the Respimat® inhaler and from a metered dose inhalator (MDI)

排除标准

  • •Patients with a significant disease other than COPD; a significant disease is defined as a disease which, in the opinion of the investigator, may (i) put the patient at risk because of participation in the study, (ii) influence the results of the study, or (iii) cause concern regarding the patient's ability to participate in the study
  • •Patients with clinically relevant abnormal baseline haematology, blood chemistry or urinalysis; all patients with a serum glutamic oxaloacetic transaminase (SGOT) > 2.5 x ULN, serum glutamic pyruvic transaminase (SGPT) > 2.5 x ULN, bilirubin >2x upper limit of normal (ULN), creatinine >2 x ULN or creatinine clearance < 50 mL/min (Estimation of Glomerular Filtration Rate (GFR) by using the Cockcroft-Gault Formula) will be excluded regardless of clinical condition (a repeat laboratory evaluation will not be conducted in these patients)
  • •Patients with a history of asthma or a total blood eosinophil count ≥600/mm3
  • •Patients with any of the following conditions:
  • •a diagnosis of thyrotoxicosis
  • •a diagnosis of paroxysmal tachycardia (>100 beats per minute)
  • •a marked baseline prolongation of QT/QTc interval
  • •a history of additional risk factors for Torsade de Pointes (TdP) (e.g. heart failure, hypokalaemia, family history of Long QT Syndrome)
  • •Patients with any of the following conditions:
  • •a history of myocardial infarction within 1 year of screening visit (Visit 1)
  • •a diagnosis of cardiac arrhythmia, arterial hypertension or coronary heart disease
  • •known active tuberculosis
  • •a malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years (patients with treated basal cell carcinoma are allowed)
  • •a history of life-threatening pulmonary obstruction
  • •a history of cystic fibrosis
  • •clinically evident bronchiectasis
  • •a history of significant alcohol or drug abuse
  • •Patients who have undergone thoracotomy with pulmonary resection
  • •Patients being treated with any of the following concomitant medications:
  • •medications that prolong the QT/QTc interval since the effects of BI 1744 CL on QT/QTc interval have yet to be fully characterized
  • •oral β-adrenergics
  • •β-blockers (topical β -blockers for ocular conditions are allowed)
  • •oral corticosteroid medication at unstable doses (i.e., less than six weeks on a stable dose) or at doses in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day
  • •Patients who regularly use daytime oxygen therapy for more than one hour per day and in the investigator's opinion will be unable to abstain from the use of oxygen therapy during clinic visits
  • •Patients who have completed a pulmonary rehabilitation program in the six weeks prior to the Screening Visit (Visit 1) or patients who are currently in a pulmonary rehabilitation program
  • •Patients who have taken an investigational drug within one month or six half lives (whichever is greater) prior to Screening Visit (Visit 1)
  • •Patients with known hypersensitivity to β-adrenergics and/or anticholinergic drugs, benzalkonium chloride, ethylenediaminetetraacetic acid or any other component of the Respimat® inhalation solution delivery system
  • •Pregnant or nursing women
  • •Women of childbearing potential not using two highly effective methods of birth control (one barrier and one non-barrier). Highly effective methods of birth control are defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or vasectomised partner. Female patients will be considered to be of childbearing potential unless surgically sterilised by hysterectomy or bilateral tubal ligation, or post-menopausal for at least two years
  • •Patients who have previously been randomized in this study or are currently participating in another study
  • •Patients who are unable to comply with pulmonary medication restrictions prior to randomization
  • •According to Inclusion Criterion No. 2, patients with a post-bronchodilator FEV1 of < 30% of predicted normal will always be excluded. Patients with a post-bronchodilator FEV1 between 30 and 50% of predicted normal will be excluded from the study, if they display additional symptoms of chronic respiratory insufficiency or right ventricular insufficiency
  • •Patients with narrow angle glaucoma, prostate hyperplasia, or bladder neck obstruction

研究组 & 干预措施

BI 1744 CL/Tiotropium FDC

Experimental

干预措施: BI 1744 CL/Tiotropium FDC (Drug)

BI 1744 CL

Active Comparator

干预措施: BI 1744 CL (Drug)

Tiotropium

Active Comparator

干预措施: Tiotropium (Drug)

结局指标

主要结局

AUC(0-1h,ss) of Olodaterol

时间窗: Within 30 min before drug administration and 0:02, 0:05, 0:10, 0:15, 0:20, 0:40, 1:00, 2:00, 4:00, 6:00, 8:00, 12:00, 24:00 hours after drug administration on Day 21 of the actual treatment period.

Area under the concentration time curve of Olodaterol in plasma over the time interval t1=0 to t2=1 hour at steady state (AUC(0-1h,ss)). As plasma concentrations were not expected to be quantifiable over the complete dosing interval in all patients, t2 was defined as the time-point where at least 2/3 of the patients reveal quantifiable plasma concentrations of Olodaterol. Based on the given definition AUC(0-1h,ss) was selected as primary endpoint. The displayed values show adjusted gMeans and intra-subject variabilities calculated from the statistical model (ANOVA).

Cmax,ss of Olodaterol

时间窗: Within 30 min before drug administration and 0:02, 0:05, 0:10, 0:15, 0:20, 0:40, 1:00, 2:00, 4:00, 6:00, 8:00, 12:00, 24:00 hours after drug administration on Day 21 of the actual treatment period.

Maximum measured concentration of Olodaterol in plasma at steady state (Cmax,ss). The displayed values show adjusted gMeans and intra-subject variabilities calculated from the statistical model (ANOVA).

Ae(0-24h,ss) of Tiotropium

时间窗: Intervals 0-4, 4-8, 8-12 and 12-24 hours on Day 21 of the actual treatment period.

Amount of Tiotropium that was eliminated in urine at steady state from time point 0 to 24 h post-inhalation (Ae(0-24h,ss)). The displayed values show adjusted gMeans and intra-subject variabilities calculated from the statistical model (ANOVA).

次要结局

  • Ae(0-24h,ss) of Olodaterol(Intervals 0-4, 4-8, 8-12 and 12-24 hours on Day 21 of the actual treatment period.)
  • Cmax,ss of Tiotropium(Within 30 min before drug administration and 0:02, 0:05, 0:10, 0:15, 0:20, 0:40, 1:00, 2:00, 4:00, 6:00, 8:00, 12:00, 24:00 hours after drug administration on Day 21 of the actual treatment period.)
  • AUC(0-6h,ss) of Tiotropium(Within 30 min before drug administration and 0:02, 0:05, 0:10, 0:15, 0:20, 0:40, 1:00, 2:00, 4:00, 6:00, 8:00, 12:00, 24:00 hours after drug administration on Day 21 of the actual treatment period.)
  • AUC(0-2h,ss) of Olodaterol(Within 30 min before drug administration and 0:02, 0:05, 0:10, 0:15, 0:20, 0:40, 1:00, 2:00, 4:00, 6:00, 8:00, 12:00, 24:00 hours after drug administration on Day 21 of the actual treatment period.)
  • fe(0-24,ss) of Olodaterol(Within 30 min before drug administration and 0:02, 0:05, 0:10, 0:15, 0:20, 0:40, 1:00, 2:00, 4:00, 6:00, 8:00, 12:00, 24:00 hours after drug administration on Day 21 of the actual treatment period.)
  • Tmin,ss of Olodaterol(Within 30 min before drug administration and 0:02, 0:05, 0:10, 0:15, 0:20, 0:40, 1:00, 2:00, 4:00, 6:00, 8:00, 12:00, 24:00 hours after drug administration on Day 21 of the actual treatment period.)
  • AUC(0-4h,ss) of Tiotropium(Within 30 min before drug administration and 0:02, 0:05, 0:10, 0:15, 0:20, 0:40, 1:00, 2:00, 4:00, 6:00, 8:00, 12:00, 24:00 hours after drug administration on Day 21 of the actual treatment period.)
  • AUC(0-tz,ss) of Olodaterol(Within 30 min before drug administration and 0:02, 0:05, 0:10, 0:15, 0:20, 0:40, 1:00, 2:00, 4:00, 6:00, 8:00, 12:00, 24:00 hours after drug administration on Day 21 of the actual treatment period.)
  • AUC(0-tz,ss) of Tiotropium(Within 30 min before drug administration and 0:02, 0:05, 0:10, 0:15, 0:20, 0:40, 1:00, 2:00, 4:00, 6:00, 8:00, 12:00, 24:00 hours after drug administration on Day 21 of the actual treatment period.)
  • Tmax,ss of Olodaterol(Within 30 min before drug administration and 0:02, 0:05, 0:10, 0:15, 0:20, 0:40, 1:00, 2:00, 4:00, 6:00, 8:00, 12:00, 24:00 hours after drug administration on Day 21 of the actual treatment period.)
  • Tmax,ss of Tiotropium(Within 30 min before drug administration and 0:02, 0:05, 0:10, 0:15, 0:20, 0:40, 1:00, 2:00, 4:00, 6:00, 8:00, 12:00, 24:00 hours after drug administration on Day 21 of the actual treatment period.)
  • fe(0-24,ss) of Tiotropium(Within 30 min before drug administration and 0:02, 0:05, 0:10, 0:15, 0:20, 0:40, 1:00, 2:00, 4:00, 6:00, 8:00, 12:00, 24:00 hours after drug administration on Day 21 of the actual treatment period.)
  • Cmin,ss of Tiotropium(Within 30 min before drug administration and 0:02, 0:05, 0:10, 0:15, 0:20, 0:40, 1:00, 2:00, 4:00, 6:00, 8:00, 12:00, 24:00 hours after drug administration on Day 21 of the actual treatment period.)
  • Concentration of Tiotropium in Plasma(Within 30 min before drug administration and 0:02, 0:05, 0:10, 0:15, 0:20, 0:40, 1:00, 2:00, 4:00, 6:00, 8:00, 12:00, 24:00 hours after drug administration on Day 21 of the actual treatment period.)
  • Cmin,ss of Olodaterol(Within 30 min before drug administration and 0:02, 0:05, 0:10, 0:15, 0:20, 0:40, 1:00, 2:00, 4:00, 6:00, 8:00, 12:00, 24:00 hours after drug administration on Day 21 of the actual treatment period.)
  • Tmin,ss of Tiotropium(Within 30 min before drug administration and 0:02, 0:05, 0:10, 0:15, 0:20, 0:40, 1:00, 2:00, 4:00, 6:00, 8:00, 12:00, 24:00 hours after drug administration on Day 21 of the actual treatment period.)
  • Concentration of Olodaterol in Plasma(Within 30 min before drug administration and 0:02, 0:05, 0:10, 0:15, 0:20, 0:40, 1:00, 2:00, 4:00, 6:00, 8:00, 12:00, 24:00 hours after drug administration on Day 21 of the actual treatment period.)
  • FVC Change From Baseline(0:30 and 1:00 h after drug administration on the first day of each treatment period)
  • FEV1 Change From Baseline(0:30 and 1:00 h after drug administration on the first day of each treatment period)
  • Clinical Relevant Abnormalities in Vital Signs, Physical Examination, Blood Chemistry, Haematology, Urinanalysis and ECG(From drug administration until 14 days following the last drug administration)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验

已完成
4 期
Study to Evaluate the Effects of Tiotropium Bromide on Chronic Obstructive Pulmonary Disease (COPD) During ExerciseCOPD
NCT00412204McMaster University20
已完成
1 期
Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Free Combination of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female VolunteersHealthy
NCT02220660Boehringer Ingelheim32
已完成
1 期
Pharmacokinetics of the Fixed Dose Combination of Tiotropium Plus BI 54903 Versus the Combination of the Monoproducts of Tiotropium and BI 54903 in Healthy VolunteersHealthy
NCT01309139Boehringer Ingelheim36
已完成
1 期
Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female VolunteersHealthy
NCT02222428Boehringer Ingelheim36
已完成
3 期
Comparison of Tiotropium Inhalation Capsules and Oxitropium Metered Dose Inhalator (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)Pulmonary Disease, Chronic Obstructive
NCT02172430Boehringer Ingelheim161